Purpose

The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • pregnant between 10 and 22 weeks gestation - 18 years of age or older - provides signed and dated informed consent - subject is at increased risk for fetal aneuploidy - subject is willing to undergo a CVS and/or amniocentesis procedure for the purpose of genetic analysis - subject agrees to provide the genetic results of the invasive procedure

Exclusion Criteria

  • Fetal demise at time of specimen sampling - Previous sample donation under this protocol

Study Design

Phase
Study Type
Observational
Observational Model
Case-Only
Time Perspective
Prospective

Recruiting Locations

University of Alabama Birmingham
Birmingham, Alabama 35294
Contact:
Rachel Copper
205 934-5509
rachel.copper@obgyn.uab.edu

Cedars-Sinai Medical Center
Los Angeles, California 90048
Contact:
Deebra Smith, MD
310- 423-5860

Sharp-Rees Stealy Medical Group
San Diego, California 92101
Contact:
Mary LaPage
619 446-1624

UCSD
San Diego, California 92121
Contact:
Jason Chibuck
jchibuck@ucsd.edu

Women's Health Care Research
San Diego, California 92123
Contact:
Nora Martinez
858 505-8672
research@womenwellness.com

Specialty Obstetrics of San Diego
San Diego, California 92130
Contact:
Deborah Malone
858 794-7700
d.malone@specialtyobstetrics.com

Reproductive Genetics Institute
Chicago, Illinois 60602
Contact:
Denise Ginsberg
773 472-4900

University of Iowa Health Care
Iowa City, Iowa 52242
Contact:
Diedre Fleener
319 356-2913
deidre-fleener@uiowa.edu

Henry Ford Hospital
Detroit, Michigan 48202
Contact:
Ellen Martindell
313 916-3190
emartin1@hfhs.org

Spectrum Health
Grand Rapids, Michigan 49503
Contact:
Yvonne Edgerly
616 391-5066

The Cooper Health System
Camden, New Jersey
Contact:
Clare Hanson
hansen-clare@cooperhealth.edu

Medical University of South Carolina
Charleston, South Carolina 29466
Contact:
Betty Oswald
843 792-0347
oswaldbw@musc.edu

More Details

Status
Recruiting
Sponsor
Sequenom, Inc.

Study Contact

Detailed Description

To collect specimens for the purpose of developing a prenatal aneuploidy test. The test will analyze circulating cell free fetal (ccff) nucleic acid from blood samples from pregnant women who have an increased risk indicator/s for fetal chromosomal aneuploidy and are undergoing invasive prenatal diagnosis by chorionic villus sampling (CVS) and/or genetic amniocentesis. The results of the ccff aneuploidy test will be compared to the chromosomal analysis obtained via CVS or genetic amniocentesis.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.